Navigation Links
Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Date:9/8/2009

ted antibodies in combination with a wide range of anti-cancer agents, including many commonly prescribed chemotherapeutic drugs. This patent was granted to the University of Texas System and is exclusively licensed to Peregrine Pharmaceuticals.

The Phase II trial of bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients has a Simon two-stage design. In the first stage, 15 patients with advanced breast cancer were enrolled and treated with the combination regimen. Nine of the 14 (64%) evaluable patients in this cohort demonstrated an objective tumor response according to RECIST criteria, exceeding the pre-specified primary efficacy endpoint needed to expand enrollment in the trial. An additional 31 patients were then enrolled to achieve the planned study total of 46 patients overall.

"Completion of patient enrollment in our second Phase II breast cancer study marks another milestone for the bavituximab cancer program, with two of our three ongoing Phase II trials now having completed enrollment," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "We believe the rapid enrollment experienced in all three of these trials is representative of the enthusiasm of our clinical investigators as well as the need for improved cancer therapies. We look forward to reporting further data from these studies in the upcoming months."

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. They may continue to receive bavituximab as monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a ... regenerative medicine, announced today that it will host ... on Tuesday, July 29, 2014, at 4:30 p.m. ... an overview of Asterias, business strategy and product ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the ...
(Date:7/24/2014)... have yet to materialise. Yet, scientists are making ... computers faster. One such approach relies on quantum ... applying an electric field. A new study demonstrates ... quantum dots (TQDs) with electrical impulses can help ... should TQDs be used as quantum information units, ...
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Genomics and Proteomics Analytical Instruments Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the study of ... study of the structure and functions of proteomes or ... tools and technology. Genomics involves the mapping of genes ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... NEW YORK, April 16 NexGenix Pharmaceuticals, presented,data ... Annual Meeting of the AACR,in San Diego today. ... on NXD30001, one of several novel, radicicol-based,Hsp90 inhibitors ... in breast cancer tumor xenograft models,without evidence for ...
... April 16 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... inhibitors demonstrating a high degree of target,specificity, strong ... tumor,tissue and significant antitumor activity and safety in ... protein chaperone that acts to stabilize and/or activate ...
... ROCKVILLE, Md., April 16 The Board of ... that Dr. Danong Chen has,been elected as the ... Chen,was previously the President and CEO of Tanox ... by Genentech in 2007.,Previously Dr. Chen was Vice-President ...
Cached Biology Technology:NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 4Danong Chen appointed CEO of Theranostics Health 2
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, ... devices, has cut emergency room wait times by an ... (UCSD) Medical Center, according to a recent study published ... Departments are using the suite to access data from ... defibrillators. "Using Geneva,s technology platform we have ...
(Date:7/24/2014)... disturbance has different effects on different species of ... Universities of Bristol and Exeter which tested fish ... to a flying seagull predator model when exposed ... in European minnows. , Lead author Dr ... said: "Noise levels in many aquatic environments have ...
(Date:7/24/2014)... June 24, 2014 Some sticky research out of ... against a certain species of toxic grass fungus: moose ... month,s Biology Letters , "Ungulate saliva inhibits a ... applied to red fescue grass (which hosts a fungus ... in slower fungus growth and less toxicity. , "Plants ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Moose drool inhibits growth of toxic fungus: York U research 2
... set of proteins found in our intestines can recognize and ... surfaces, scientists at Emory University School of Medicine have discovered. ... scheduled to appear in the journal Nature Medicine . ... on the surfaces of bacteria, but these proteins are different ...
... remember the muscle shirts we wore in our teens and 20s? ... usually is obsolete. Yes, at the big 4-0 we begin to ... it may be gone. It,s an inevitable process of aging called ... A study conducted in mice with accelerated muscle loss at The ...
... scientists at the University of Missouri Center for Agroforestry ... can trap and break down veterinary antibiotics in manure ... can be effective in protecting water quality, controlling erosion ... beauty of it," said Keith Goyne, assistant professor of ...
Cached Biology News:Bacteria-killing proteins cover blood type blind spot 2Bacteria-killing proteins cover blood type blind spot 3Muscle loss finding may one day save physiques 2Plant buffers may limit spread of antibiotics in animal waste 2
... The thermostable dUTPase(pyrococcus fruriosus) ... (using proofreading DNA polymerases). It ... reactions and dNTP solutions. The ... DNA polymerase reaction can prevent dUTP ...
... AVOID FREEZE/THAW CYCLES. An assay kit designed ... Western blotting. PARP is an enzyme implicated ... apoptosis, PARP is cleaved by caspase-3. Cleavage ... to 85 kDa is a hallmark of ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Many other sizes and custom ...
... save space and organize gloves, ... other garb. They are the ... small parts used in labs, ... Open-slot design for easy cleaning. ...
Biology Products: